Journal article · 2025 · Open access

CREATION OF A NEW PATIENT REPORTED OUTCOME FOR A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SSc USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES: THE CRISTAL PRO

Alain Lescoat, Yen T. Chen, Rosemary J. Gedert, Neda Kortam, Nadia Vann, David F Cella, Sara L. Shaunfield, Susan Lynn Murphy, D. Khanna

Annals of the Rheumatic Diseases, 84, 1097–1098 · Published 1 June 2025 · DOI 10.1016/j.ard.2025.06.336

Open full textCite this paper

In brief

“CREATION OF A NEW PATIENT REPORTED OUTCOME FOR A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SSc USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES: THE CRISTAL PRO” is a 2025 journal article by Alain Lescoat and 8 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 0 citations as of 22 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Annals of the Rheumatic Diseases.

Citations
0
Authors
9

Abstract

Background: Limited cutaneous systemic sclerosis (lcSSc) is the largest subset of scleroderma, yet there is a paucity of outcome measures to assess symptoms that are important to patients with lcSSc. The CRISTAL project, an international initiative, aims to create a combined response index for lcSSc for use in clinical trials (the CRISTAL index). A key milestone of CRISTAL is the development of a novel patient reported outcome measure (PROM) to assess the most common and/or bothersome symptoms experienced by patients with lcSSc. Objectives: The objective was to create a PROM that assesses the overall symptom experience of lcSSc, following FDA guidance for the creation of PROM. Methods: The CRISTAL PROM was constructed using an iterative approach that included patient partners at each step (Figure 1). [1]/Concept elicitation: Face and content validity and domain elicitation were derived through prior focus groups of patients with lcSSc (Lescoat et al. 2022). 2/Item identification and concept mapping: Existing PROM items from PROMIS item banks were mapped to symptoms reflecting general domains (pain, fatigue, cognition, sleep) identified from the focus groups. Existing PROMs from lcSSc-specific domains were identified from the literature. New items were drafted with a patient partner for domains with without existing PROM items (i.e., digital ulcers, calcinosis). 3/Item selection: Items from lcSSc-specific domains were then selected through a patient-centered online survey where patients rated each item on a 5-point scale from "not relevant" to "extremely relevant". The results informed the development of a draft CRISTAL PROM. 4/Cognitive debriefing: the draft CRISTAL PROM was revised through cognitive interviews with patients with lcSSc to evaluate comprehension and relevance. Results: Twelve general items were selected from PROMIS item banks based on analyses of focus groups. Twenty six patients with lcSSc were included in the PROM item-rating survey (median disease duration=4.0 years, 88.5% women); 63 items were rated on relevance. The top 3-4 items with the highest relevance rating per domain were included in the first version of the CRISTAL PROM which included 41 items. This version underwent cognitive debriefing with 18 lcSSc patients (median disease duration 6.0 years, 94.4% women). The CRISTAL PROM V1 was refined through an iterative process based on patients' insights. The final preliminary CRISTAL PROM includes 37 items assessing symptom experiences reflecting 4 general and 8 lcSSc-specific domains, with a recall period of 7 days. Conclusion: The preliminary CRISTAL PROM was developed to assess the symptoms that are common and/or bothersome in patients with lcSSc. We are currently assessing the psychometric properties of the CRISTAL PROM in a longitudinal multicenter international…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Lescoat, A., Chen, Y. T., Gedert, R. J., Kortam, N., Vann, N., Cella, D. F., Shaunfield, S. L., Murphy, S. L., & Khanna, D. (2025). CREATION OF A NEW PATIENT REPORTED OUTCOME FOR A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SSc USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES: THE CRISTAL PRO. Annals of the Rheumatic Diseases, 84, 1097–1098. https://doi.org/10.1016/j.ard.2025.06.336

MLA 9

Lescoat, Alain, et al. “CREATION OF A NEW PATIENT REPORTED OUTCOME FOR A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SSc USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES: THE CRISTAL PRO.” Annals of the Rheumatic Diseases, vol. 84, 2025, pp. 1097–1098. https://doi.org/10.1016/j.ard.2025.06.336.

Chicago

Lescoat, Alain, Yen T. Chen, Rosemary J. Gedert, Neda Kortam, Nadia Vann, David F Cella, Sara L. Shaunfield, Susan Lynn Murphy, and D. Khanna. 2025. “CREATION OF A NEW PATIENT REPORTED OUTCOME FOR A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SSc USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES: THE CRISTAL PRO.” Annals of the Rheumatic Diseases 84: 1097–1098. https://doi.org/10.1016/j.ard.2025.06.336.

Harvard

Lescoat, A. et al. (2025) ‘CREATION OF A NEW PATIENT REPORTED OUTCOME FOR A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SSc USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES: THE CRISTAL PRO’, Annals of the Rheumatic Diseases, 84, pp. 1097–1098. doi:10.1016/j.ard.2025.06.336.

IEEE

A. Lescoat et al., “CREATION OF A NEW PATIENT REPORTED OUTCOME FOR A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SSc USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES: THE CRISTAL PRO,” Annals of the Rheumatic Diseases, vol. 84, pp. 1097–1098, 2025, doi: 10.1016/j.ard.2025.06.336.

BibTeX

@article{lescoat2025creation,
  title     = {{CREATION OF A NEW PATIENT REPORTED OUTCOME FOR A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SSc USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES: THE CRISTAL PRO}},
  author    = {Lescoat, Alain and Chen, Yen T. and Gedert, Rosemary J. and Kortam, Neda and Vann, Nadia and Cella, David F and Shaunfield, Sara L. and Murphy, Susan Lynn and Khanna, D.},
  journal   = {Annals of the Rheumatic Diseases},
  year      = {2025},
  volume    = {84},
  pages     = {1097--1098},
  doi       = {10.1016/j.ard.2025.06.336},
  url       = {https://doi.org/10.1016/j.ard.2025.06.336}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases

  • limited cutaneous systemic sclerosis
  • patient-reported outcome measures
  • symptom assessment
  • concept mapping
  • cognitive debriefing
  • patient partners
  • digital ulcers
  • calcinosis

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Lescoat, A., Chen, Y. T., Gedert, R. J., Kortam, N., Vann, N., Cella, D. F., Shaunfield, S. L., Murphy, S. L., & Khanna, D. (2025). CREATION OF A NEW PATIENT REPORTED OUTCOME FOR A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SSc USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES: THE CRISTAL PRO. Annals of the Rheumatic Diseases, 84, 1097–1098. https://doi.org/10.1016/j.ard.2025.06.336

How many times has this paper been cited?

0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the full text from this page.

Who wrote this paper?

Alain Lescoat, Yen T. Chen, Rosemary J. Gedert, Neda Kortam, Nadia Vann, David F Cella, Sara L. Shaunfield, Susan Lynn Murphy, D. Khanna.

What is the DOI of this paper?

10.1016/j.ard.2025.06.336, permanently at https://doi.org/10.1016/j.ard.2025.06.336. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.